A major shift is underway in how medicine uses artificial intelligence and genomic data to predict disease and guide treatment. Weill Cornell Medicine has created the Department of Systems and Computational Biomedicine, a new research unit designed to integrate large-scale patient datasets with AI algorithms to unlock insights into disease development and prevention. Simultaneously, rapid whole-genome sequencing is moving from research labs into routine clinical care at major hospitals, a transition that is forcing clinical trial sponsors to fundamentally rethink how they design studies and manage patient data.

What Is the Department of Systems and Computational Biomedicine?

Weill Cornell Medicine announced on August 24, 2026, that Dr. Dan Landau, an internationally recognized cancer researcher and geneticist, will serve as the inaugural chair of the new Department of Systems and Computational Biomedicine, effective September 1. The department consolidates existing research units and represents a multiyear effort to reorganize how the institution approaches basic and translational science.

The department's mission is ambitious: to combine advanced genomics, patient-focused technologies, and computational approaches, including artificial intelligence, to gain unprecedented insights into what drives disease. The goal is to enable scientists to predict health risks more precisely and develop intervention strategies before disease occurs.

"Our ability to produce patient-derived data at a scale never before imagined is complemented by artificial intelligence, enabling us to use this data in exciting new ways. This convergence is a really unique moment in the history of biomedical sciences and one that gives us a mandate to dream big," said Dr. Dan Landau.

Dr. Dan Landau, Inaugural Chair of the Department of Systems and Computational Biomedicine at Weill Cornell Medicine

The department's creation is funded in part by a $20 million gift from philanthropists Andrew and Ann Tisch to Cornell University. Dr. Landau will become the Andrew H. and Ann R. Tisch Professor of Systems and Computational Biomedicine.

How Will the Department Build Its AI-Powered Research Platform?

A central goal of the new department is constructing large datasets that integrate information from multiple sources. These datasets will serve as the foundation for AI models that can help reimagine core aspects of medical care.

• Data Integration: The department will combine DNA sequencing results, other molecular profiling data, physiological monitoring from wearable health devices, electronic health records, medical imaging, and clinical outcomes into unified datasets.
• Measurement Innovation: The department will establish an innovation laboratory focused on developing new molecular measurement technologies for the AI era, allowing Weill Cornell to generate high-dimensional biological datasets at scale.
• Collaborative Recruitment: The department plans to recruit five to seven junior faculty members and one to two mid-career investigators in computational biology and artificial intelligence, with emphasis on individuals who can bridge basic science and clinical medicine.
• Physical Infrastructure: Weill Cornell has committed to providing new laboratory space at 1334 York Avenue, including a large molecular innovation laboratory focused on developing new data-generation technologies.

"Historically, many of the largest scientific advances have followed advances in measurement technology. We will establish an innovation laboratory focused on molecular measurement technologies for the AI era, to allow Weill Cornell to create its own high-dimensional biological datasets at scale," explained Dr. Landau.

Dr. Dan Landau, Inaugural Chair of the Department of Systems and Computational Biomedicine at Weill Cornell Medicine

Why Is Rapid Genome Sequencing Becoming Standard Care?

While Weill Cornell is building its AI infrastructure, a parallel transformation is already underway in clinical practice. Rapid whole-genome sequencing, or rWGS, is transitioning from an investigational tool used only in research settings to a standard-of-care procedure in pediatric intensive care units.

The Dubai LITTLE FALCON program, described in a Nature Medicine paper published in August 2026, demonstrates this shift. The program deployed rapid whole-genome sequencing across multiple pediatric ICUs simultaneously in a single city, enrolling 100 critically ill pediatric patients from 18 Middle Eastern and Asian countries. The program returned actionable diagnoses in a mean of 3.4 days, not as a research protocol but as standard clinical infrastructure.

Similarly, on August 24, 2026, GeneDx announced findings from a study published in Genetics in Medicine showing that Seattle Children's Hospital has adopted hospital-wide rapid genome sequencing, covering over 1,000 pediatric inpatients across the neonatal ICU, pediatric ICU, and cardiac ICU. This represents a fundamental shift in how hospitals treat genomic data: as a routine input to clinical decision-making, similar to a complete blood count.

The speed and cost improvements are driving this adoption. The Rady Children's Institute for Genomic Medicine achieved a median time to diagnosis of 20 hours and 10 minutes using bead-based library preparation and 15.5-hour sequencing. The cost per diagnosis is approximately $14,082, making it competitive with a week in a pediatric ICU without a diagnosis to guide treatment.

What Does This Mean for Clinical Trial Design?

The rapid adoption of genome sequencing as standard care is creating an immediate problem for clinical trial sponsors, particularly those running rare disease and pediatric studies. If a hospital has already adopted rWGS as routine care, patients may arrive at trial enrollment with genomic diagnoses already in hand, generated by the hospital's standard workflow rather than the trial's investigational procedures.

This creates three concrete challenges for trial design. First, enrollment timelines become obsolete: if rWGS returns results in 3.4 days and a trial's run-in period assumes a 30-day diagnostic workup, the study's assumptions about patient availability are no longer valid. Second, randomization integrity is at risk: sites using AI-driven variant interpretation as standard care may be stratifying patients on genomic data that the trial's statistical analysis plan has not accounted for. Third, institutional review boards at hospitals with embedded rWGS infrastructure will question whether trial consent forms address incidental findings generated by the hospital's clinical workflow, a scenario most standard consent templates do not address.

A randomized trial published in JAMA Pediatrics in December 2021 compared early clinical whole-genome sequencing results, returned within 15 days, against standard care in 354 acutely ill infants with a mean age of 15 days. The trial showed a measurable shift in clinical management. If a pediatric trial's primary endpoint involves treatment decisions made in that same early window, and the site is now operating with rWGS as infrastructure rather than intervention, the trial may inadvertently treat the intervention as background noise.

What Should Trial Sponsors Do Now?

For medical directors and clinical operations leaders running rare disease, inborn error of metabolism, or neonatal programs, site feasibility assessments need a new critical question: "Does this site use rWGS as standard of care, and if so, what is their mean diagnostic turnaround?" The answer changes enrollment models, stratification assumptions, and data management plans for handling pre-existing genomic data that arrived outside the trial's chain of custody.

The FDA's Clinical Decision Support Software guidance, finalized in 2022, has not been revised to address the operational reality of citywide genomic infrastructure. Sponsors who assume the current regulatory framework is stable enough to build a five-year pediatric rare disease program are making a bet that the agency will not revisit how AI-driven variant interpretation is classified as the technology scales from academic centers to municipal health systems. Given that LITTLE FALCON spans 18 countries and Seattle Children's has crossed 1,000 patients, that regulatory window is narrowing.

The FDA's Pediatric Advisory Committee calendar and the agency's Digital Health Center of Excellence output through the end of 2026 will be critical to watch. The first advisory committee discussion that places hospital-wide rWGS infrastructure in the context of trial data integrity will likely trigger a protocol amendment wave across every active pediatric rare disease investigational new drug application that touches a site operating at scale.

How Does This Connect to Weill Cornell's New Department?

The convergence of these two developments, AI-powered genomic research at Weill Cornell and rapid genome sequencing becoming standard care in hospitals, reflects a broader transformation in biomedicine. Dr. Landau emphasized that AI applications thrive at larger scales, which is why the new department is designed around collaboration rather than individual labs. The department will leverage relationships with Cornell's other campuses, peer scientific and clinical centers in New York City, and biotech and AI leaders.

This collaborative approach mirrors the operational reality demonstrated by LITTLE FALCON and Seattle Children's: genomic medicine at scale requires coordination across institutions, standardized data formats, and AI systems that can process patient information from multiple sources simultaneously. Weill Cornell's new department is positioning itself to lead this transformation by building the infrastructure, recruiting the talent, and developing the measurement technologies that will enable the next generation of AI-powered precision medicine.